−64.40USD
−20.25 MUSD
570.00 KUSD
539.35 K
About Vaccinex, Inc.
Sector
Industry
CEO
Maurice Zauderer
Website
Headquarters
Rochester
Employees (FY)
40
Founded
1997
ISIN
US9186403013
FIGI
BBG00469NFK4
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VCNX is 4.80 USD — it has decreased by 0.83% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vaccinex, Inc. stocks are traded under the ticker VCNX.
Vaccinex, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
VCNX stock is 16.88% volatile and has beta coefficient of 0.37. Check out the list of the most volatile stocks — is Vaccinex, Inc. there?
VCNX earnings for the last quarter are −27.30 USD whereas the estimation was −56.70 USD which accounts for 51.85% surprise. Estimated earnings for the next quarter are −56.70 USD. See more details about Vaccinex, Inc. earnings.
Vaccinex, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 107.00 K USD. In the next quarter revenue is expected to reach 50.00 K USD.
Yes, you can track Vaccinex, Inc. financials in yearly and quarterly reports right on TradingView.
VCNX stock has fallen by 32.77% compared to the previous week, the month change is a 41.96% fall, over the last year Vaccinex, Inc. has showed a 94.69% decrease.
VCNX net income for the last quarter is −3.32 M USD, while the quarter before that showed −4.91 M USD of net income which accounts for 32.47% change. Track more Vaccinex, Inc. financial stats to get the full picture.
Today Vaccinex, Inc. has the market capitalization of 6.90 M, it has increased by 5.04% over the last week.
No, VCNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VCNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vaccinex, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 40.00 employees. See our rating of the largest employees — is Vaccinex, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vaccinex, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vaccinex, Inc. stock shows the sell signal. See more of Vaccinex, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vaccinex, Inc. EBITDA is −22.77 M USD, and current EBITDA margin is −3.99 K%. See more stats in Vaccinex, Inc. financial statements.